Systematic review of antiprotozoal potential of antimicrobial peptides

FA Santos, GS Cruz, FA Vieira, BRS Queiroz… - Acta Tropica, 2022 - Elsevier
Protozoa is a group of microorganisms that cause neglected tropical diseases, such as
malaria, Chagas disease, and Leishmaniasis. Due to the growing demand for new …

Cytokines in the immunity and immunopathogenesis in leishmaniases

B Saha, R Silvestre - Cytokine, 2021 - Elsevier
Cytokines are key mediators of immune responses to autoantigens, tumor antigens and
foreign antigens including pathogens and transplant antigens. The cytokines are produced …

Exploring the permeability of Amphotericin B trough serum albumin dispersions and lipid nanocarriers for oral delivery

HR Marcelino, A Solgadi, M Chéron… - International Journal of …, 2023 - Elsevier
Amphotericin B (AmB) is a potent polyenic antifungal agent with leishmanicidal activity. Due
to its low solubility and permeability in the gastrointestinal tract, AmB is usually administered …

SHIP1 inhibition via 3-alpha-amino-cholestane enhances protection against Leishmania infection

BP Chowdhury, S Das, N Bodhale, SP Pandey… - Cytokine, 2023 - Elsevier
Leishmania major and L. donovani cause cutaneous leishmaniasis and visceral
leishmaniasis, respectively. Available chemotherapies suffer from toxicity, drug-resistance or …

Activation of neutrophils excels the therapeutic potential of Mycobacterium indicus pranii and heat‐induced promastigotes against antimony‐resistant Leishmania …

K Roy, S Ghosh, M Karan, S Karmakar… - Scandinavian …, 2024 - Wiley Online Library
Repurposing drugs and adjuvants is an attractive choice of present therapy that reduces the
substantial costs, chances of failure, and systemic toxicity. Mycobacterium indicus pranii was …

Discovery of Leishmania Druggable Serine Proteases by Activity-Based Protein Profiling

EOJ Porta, JA Isern, K Kalesh, PG Steel - Frontiers in Pharmacology, 2022 - frontiersin.org
Leishmaniasis are a group of diseases caused by parasitic protozoa of the genus
Leishmania. Current treatments are limited by difficult administration, high cost, poor …

Addressing anemia severity in antimony-resistant Leishmania donovani infection at the nexus of oxidative outburst and iron transit

S Ghosh, KV Chigicherla, S Dasgupta, Y Goto… - bioRxiv, 2024 - biorxiv.org
Despite the withdrawal of pentavalent-antimonials in treating Visceral leishmaniasis for
more than a decade, recent clinical isolates of Leishmania donovani (LD) exhibit …

[PDF][PDF] Prevalence of Anti-parasitic Drug Resistance in Various Areas of the World

A Haraguchi, B Harris, N Feasby… - Indian Journal of Veterinary …, 2024 - ijvph.org
Parasites are organisms that cause awide range of diseasesall over the world. Like other
disease-causing agents, parasites can develop resistance to drugs used to treat them, often …

[PDF][PDF] Mediterr J Infect Microb Antimicrob 2022; 11: 21 Erişim: http://dx. doi. org/10.4274/mjima. galenos. 2022.2021. 21 review Pharmacological Approaches to …

C Sellitto, G Scarpati, T Ascione, G Franci, O Piazza… - researchgate.net
Visceral Leishmaniasis (VL) is a chronic parasitosis, hypo-endemic in the Mediterranean
area, but hyperendemic in areas such as Bihar, Sudan, and North-eastern Brazil …